The success of Sildenafil initially fueled a surge for major pharmaceutical companies, nevertheless recent developments present a murky scenario for investors. Off-patent competitors are eating into revenue, and https://safambqm443576.frewwebs.com/40202298/the-blue-pill-and-big-pharma-a-precarious-investment